Denosumab for Breast Cancer With Bone Mets
Denosumab for Breast Cancer With Bone Mets
The goal of this clinical research study is to learn if denosumab in combination with a
 hormonal drug can help lower the number of circulating tumor cells (CTCs) in patients with
 breast cancer that has spread to the bone. The safety of this combination will also be
 studied.

 This is an investigational study. Denosumab is FDA approved and commercially available to
 prevent bone-related events caused by breast cancer that has spread to the bone. Using
 denosumab to lower CTCs in patients with breast cancer that has spread to the bone is
 investigational.

 You may have the option of continuing denosumab after the study ends.

 Up to 35 patients will take part in this study. All will be enrolled at MD Anderson.
Study Drug Administration:

 If you are found to be eligible to take part in this study, you will receive denosumab
 through a needle under your skin on Day 1 of each 28-day study cycle.

 Starting on Day 1 of week 4, you will also begin taking a hormonal drug. The study doctor
 will choose the hormonal drug you receive based on your previous hormonal therapy for breast
 cancer. The study doctor will give you instructions for taking your hormonal drug.

 Study Visits:

 On Day 1 of week 4:

 -  You will have a physical exam

 -  Blood (about 3 tablespoons) will be drawn for routine tests

 -  Blood (about 5 teaspoons) will be drawn for CTC testing and to check your immune system.

 -  Urine will be collected to test for a biomarker that is used to measure the rate of bone
 breakdown.

 -  If the study doctor thinks it is needed, you will have a PET scan, a bone scan, or an
 MRI to check the status of the disease.

 On Day 1 of Cycle 2 and Cycle 3, blood (about 1 teaspoon) will be drawn for routine tests.

 Length of Study:

 You may receive the denosumab and hormonal therapy combination for up to 13 weeks. You will
 be taken off study if the disease gets worse or intolerable side effects occur.

 End of Study Visit:

 After your last dose of the study drug, the following tests and procedures will be performed:

 -  You will have a physical exam.

 -  Blood (about 3 tablespoons) will be drawn for routine tests.

 -  Blood (about 5 teaspoons) will be drawn for CTC testing and to check your immune system.

 -  Urine will be collected to test for a biomarker that is used to measure the rate of bone
 breakdown.

 -  If the study doctor thinks it is needed, you will have a PET scan, a bone scan, or an
 MRI to check the status of the disease.
Inclusion Criteria:

 1. Patients have histological confirmation of breast carcinoma.

 2. Patients have progressive metastatic disease with predominantly bone metastasis with 1
 or more lesions and at least 1 bone lesion has pathological confirmation, have not
 been treated or have been treated with any prior therapies (including bisphosphonate
 treatment and/or radiation therapy). Patients can have soft tissue involvement (Lymph
 node and skin) and/or metastatic lesions at major organ sites (i.e. lung, liver, etc).

 3. Patients have positive ER expression in the primary tumor site by IHC (defined as
 >/=10%) (PR status is not required)

 4. Adequate hematologic function: 1)Absolute neutrophil count (ANC) >/= 1.0 x 10^9/L, 2)
 Platelet count >/= 50 x 10^9/L, 3) Hemoglobin >/= 9.0 g/dL

 5. Adequate cardiac function (LVEF >/= 45%) if patient has known cardiac dysfunction
 history

 6. Adequate Renal function: Calculated creatinine clearance >30 ml/min

 7. Adequate Hepatic function: 1) Aspartate aminotransferase (AST) </= 2.5 x ULN; 2)
 Alanine aminotransferase (ALT) </= 2.5 x ULN; 3) Alkaline phosphatase (Alp) </= 2.5 x
 ULN; 4) Total bilirubin </= 2.0 x ULN

 8. Serum calcium or albumin-adjusted serum calcium >/=2.0mmol/L (8.0mg/dL) and </= 2.9
 mmol/L (11.5mg/dL)

 9. Patients have ability and willingness to sign written informed consent.

 10. Patients are 18 years of age or older.

 11. Female patients of childbearing potential (A female not free from menses > 2 years or
 not surgically sterilized) must be willing to use highly effective contraception to
 prevent pregnancy or agree to abstain from heterosexual activity throughout the study.
 Highly effective contraception, defined as male condom with spermicide, diaphragm with
 spermicide, intra-uterine device. Highly effective contraception must be used by both
 sexes during the study and must be continued for 5 months after the last dose of
 denosumab.

 12. Female patients of childbearing potential must have negative serum pregnancy test </=
 21 days prior to starting study treatment.

 13. Patients have CTC >/=3.

 Exclusion Criteria:

 1. Patients have known sensitivity to any of the products to be administered during the
 study (e.g., mammalian derived products, calcium, or vitamin D).

 2. Patients receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy,
 radiation therapy and biological therapy) while taking study medication. However,
 patients receiving CDK4/6 inhibitor or mTOR inhibitor as a standard of care while on
 study is permitted.

 3. Patients with metastatic sites that requires chemotherapy.

 4. Patients with active infection and requiring IV or oral antibiotics.

 5. Patients with concurrent disease or condition that would make them inappropriate for
 study participation, or any serious medical disorder that would interfere with
 patients' safety.

 6. Patients have HER2-positive breast carcinoma (IHC staining more than 3+ or HER2 gene
 amplification by FISH)

 7. Patient is pregnant or breast feeding, or planning to become pregnant within 5 months
 after the end of treatment.

 8. Patient is of child bearing potential and is not willing to use, in combination with
 her partner, two highly effective methods of contraception or abstinence during
 treatment and for 5 months after the end of treatment.

 9. Male patients.

 10. Patients have prior history or current evidence of osteonecrosis/osteomyelitis of the
 jaw.

 11. Patients have active dental or jaw condition which requires oral surgery, including
 tooth extraction.

 12. Patients have non healed dental/oral surgery, including tooth extraction.

 13. Patients planned invasive dental procedures.

 14. Patients experiencing a visceral crisis including severe organ dysfunction as assessed
 by > Gr 2 symptomatic toxicities, laboratory studies, and/ or rapid progression of
 disease originating from visceral metastasis.

 15. Patients that have received the study medication (Xgeva/Prolia).